Inhaled Nitric Oxide Market

Inhaled Nitric Oxide Market Overview:

The global inhaled nitric oxide market size was valued at $634.4 million in 2019 and is estimated to reach $1,180.98 million by 2027, registering a CAGR of 8.1% from 2020 to 2027.

Inhaled nitric oxide has antiviral properties and improved oxygenation. Therefore, nitric oxide is now being tested as an experimental treatment for COVID-19. It is helpful in protecting healthcare workers on the front line of the pandemic from getting sick. Further, iNO is used for the treatment of pulmonary hypertension, ARDS, and other respiratory diseases, whereas several undergoing randomized clinical trials are being conducted to investigate the role of inhaled nitric oxide in COVID-19. Moreover, key players such as Mallinckrodt have also initiated a retrospective study for the use of iNO in COVID-19 patients. Moreover, multiple ongoing clinical trials are conducted for iNO as a treatment for COVID-19 and it is being used with promising results in the patient population.

Nitric oxide is a gas that is inhaled through the nose or mouth. It works by relaxing the smooth muscles to widen the blood vessels in the lungs. It is used together with a breathing machine (ventilator) and other agents to treat newborn (term and near-term) babies with respiratory failure that is caused by pulmonary hypertension.

Nitric oxide is clinically efficient in dilating blood vessels and to relax muscle tension, which absorbs oxygen efficiently in the body. Furthermore, nitric oxide is usually used together with a breathing machine (ventilator). Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in a human was first described in the 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborn with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the U.S. first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.

The major factors that contribute toward the growth of the market are increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). However, the rise in the number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) boost the growth of the inhaled nitric oxide market. However, the high cost of treatment and strict government regulations for various applications hamper the inhaled nitric oxide market growth. 

Conversely, ongoing R&D activities leading to new application areas in the healthcare industry are expected to provide lucrative opportunities for the expansion of the global inhaled nitric oxide market in the near future.

The World Health Organization (WHO) on January 30, 2020, declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. 

Inhaled nitric oxide has antiviral property and improved oxygenation; therefore, nitric oxide is now being tested as an experimental treatment for COVID-19. It is also helpful in protecting healthcare workers on the front line of the pandemic from getting sick. Further, iNO is used for the treatment of pulmonary hypertension, ARDS, and other respiratory diseases, whereas several undergoing randomized clinical trials are being conducted to investigate the role of inhaled nitric oxide in COVID-19. Moreover, key players such as Mallinckrodt have also initiated a retrospective study for the use of iNO in COVID-19 patients. Moreover, multiple ongoing clinical trials are conducted for iNO as a treatment for COVID-19 and it is being used with promising results in the patient population. 

In March, the U.S. FDA gave a handful of pharmaceutical company’s emergency clearance to allow the use of their nitric oxide devices to treat these patients, including Bellerophon Therapeutics and Vero Biotech. In addition, inhaled gas can have therapeutic benefits in COVID-19 patients by preventing further damage to the vessels inside the lungs. 

Inhaled Nitric Oxide Market Segmentation  

The inhaled nitric oxide market is segmented on the basis of application and region. By application, the market is divided into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others (tuberculosis treatment). Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and Rest of World.

Segment review 

Presently, on the basis of application, the market is divided into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others (tuberculosis treatment).

Neonatal respiratory treatment is the major revenue contributor, and is projected to grow significantly during the forecast period. This is attributed to the increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). 

Snapshot of Asia-Pacific inhaled nitric oxide market  

Asia-Pacific is expected to be a growing region shortly on account of the number of highest live birth per 1000 people and the rise in prevalence of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN). The competitive market formed due to the emergence of local providers of nitric oxide therapy systems contributes toward the growth of the Asia- Pacific market.

The key players profiled in this report include Air Liquide S.A, Bellerophon Therapeutics, Inc., BOC Healthcare, Beyond Air, Inc, Halma Plc, Linde Plc, Mallinckrodt plc, Novoteris, LLC, VERO Biotech LLC, and Nu-Med Plus.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the inhaled nitric oxide market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers inhaled nitric oxide market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis of major regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the players are thoroughly analyzed to understand the competitive outlook of inhaled nitric oxide market growth.

 Inhaled Nitric Oxide Market Report Highlights